Masking of CD22 by cis ligands does not prevent redistribution of CD22 to sites of cell contact
- 12 April 2004
- journal article
- Published by Proceedings of the National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 101 (16) , 6104-6109
- https://doi.org/10.1073/pnas.0400851101
Abstract
CD22, a negative regulator of B cell signaling, is a member of the siglec family that binds to alpha2-6-linked sialic acids on glycoproteins. Previous reports demonstrated that binding of multivalent sialoside probes to CD22 is blocked, or "masked," by endogenous (cis) ligands, unless they are first destroyed by sialidase treatment. These results suggest that cis ligands on B cells make CD22 functionally unavailable for binding to ligands in trans. Through immunofluorescence microscopy, however, we observed that CD22 on resting B cells redistributes to the site of contact with other B or T lymphocytes. Redistribution is mediated by interaction with trans ligands on the opposing cell because it does not occur with ligand-deficient lymphocytes from ST6GalI-null mice. Surprisingly, CD45, proposed as both a cis and trans ligand of CD22, was not required for redistribution to sites of cell contact, given that redistribution of CD22 was independent of CD45 and was observed with lymphocytes from CD45-deficient mice. Furthermore, CD45 is not required for CD22 masking as similar levels of masking were observed in the WT and null mice. Comparison of the widely used sialoside-polyacrylamide probe with a sialoside-streptavidin probe revealed that the latter bound a subset of B cells without sialidase treatment, suggesting that cis ligands differentially impacted the binding of these two probes in trans. The combined results suggest that equilibrium binding to cis ligands does not preclude binding of CD22 to ligands in trans, and allows for its redistribution to sites of contact between lymphocytes.Keywords
This publication has 60 references indexed in Scilit:
- Chemically Defined Sialoside Scaffolds for Investigation of Multivalent Interactions with Sialic Acid Binding Proteins†The Journal of Organic Chemistry, 2003
- A CD45 minigene restores regulated isoform expression and immune function in CD45-deficient mice: therapeutic implications for human CD45-null severe combined immunodeficiencyBlood, 2003
- I-type lectinsBiochimica et Biophysica Acta (BBA) - General Subjects, 2002
- Sialic Acid Binding Domains of CD22 Are Required For Negative Regulation of B Cell Receptor SignalingThe Journal of Experimental Medicine, 2002
- The Ligand-binding Domain of CD22 Is Needed for Inhibition of the B Cell Receptor Signal, as Demonstrated by a Novel Human CD22-specific Inhibitor CompoundThe Journal of Experimental Medicine, 2002
- Inhibition of T Cell Receptor-Coreceptor Interactions by Antagonist Ligands Visualized by Live FRET Imaging of the T-Hybridoma Immunological SynapseImmunity, 2002
- A Small Region of the Natural Killer Cell Receptor, Siglec-7, Is Responsible for Its Preferred Binding to α2,8-Disialyl and Branched α2,6-Sialyl ResiduesJournal of Biological Chemistry, 2002
- CD22 regulates thymus-independent responses and the lifespan of B cellsNature, 1996
- The B lymphocyte adhesion molecule CD22 interacts with leukocyte common antigen CD45RO on T cells and α2–6 sialyltransferase, CD75, on B cellsCell, 1991
- Expression of receptors for Fc portion of IgM (Fc.MU.R) and surface neuraminic acid on the human peripheral lymphocytes.The Tohoku Journal of Experimental Medicine, 1985